VRC-01
Based on 1 Customer Validation
VRC-01 is a broadly neutralizing IgG1 monoclonal antibody that targets HIV-1 envelope glycoprotein gp120 Protein. VRC-01 blocks HIV-1 viral entry by mimicking CD4 receptor interaction with HIV-1 gp120 and neutralizes broad HIV-1 clades. VRC-01 can be used for the research of HIV-1 infection.
For research use only. We do not sell to patients.
- Purity : 99.805%
- CAS No.: 1412901-55-3
- Molecular Weight:145.87 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
HIV-1 |
In Vitro
VRC-01 binds HIV-1 gp120 IIIB with Kd values of 1.68 nM and 1.39 nM for transient and stable tobacco plant-produced VRC-01, respectively[2].
VRC-01 (1-24 h) from transient and stable tobacco plants neutralize HIV-1 BaL in TZM-bl cells with IC50 values of 0.339 μg/mL and 0.407 μg/mL, respectively[2].
VRC-01 (1-48 h) from transient tobacco plants neutralizes a panel of 10 HIV-1 Env pseudoviruses (clades A, B, C, G), while stable plant-produced VRC-01 shows slightly reduced potency against the same panel[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized envelope glycoprotein gp120 Protein, HIV-1 (AAC31819, HEK293, His, HY-P76390) can bind VRC-01. The EC50 for this effect is 6.987 ng/mL.
Chemical Information
-
CAS No. 1412901-55-3
-
Appearance Liquid
-
Molecular Weight 145.87 kDa
-
Color Colorless to light yellow
-
SMILES
[VRC-01]
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Boesch AW, et al. Highly parallel characterization of IgG Fc binding interactions. MAbs. 2014;6(4):915-927. [Content Brief]
[2]. Teh AY, et al. Characterization of VRC01, a potent and broadly neutralizing anti-HIV mAb, produced in transiently and stably transformed tobacco. Plant Biotechnol J. 2014;12(3):300-311. [Content Brief]
[3]. Sullivan MA, et al. Anti-idiotypic monobodies derived from a fibronectin scaffold. Biochemistry. 2013;52(10):1802-1813. [Content Brief]
[4]. Stelter S, et al. Engineering the interactions between a plant-produced HIV antibody and human Fc receptors. Plant Biotechnol J. 2020;18(2):402-414. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
VRC-01 Related Classifications
HY-P991069 Related Classifications
Powered by Bioz